War Against HSWar Against HS
Daily Research Briefing

Three-Year Data Shows Bimekizumab (BIMZELX®) Achieves Significant Long-Term Improvements in Moderate to Severe HS

March 12, 2026 · War Against HS Research Intelligence

BimekizumabIL-17Phase 3Long-Term Data

DISCLAIMER: This content is for informational and educational purposes only. It is NOT medical advice. Always consult a qualified healthcare professional before making any treatment decisions. Discuss all treatments and clinical trial opportunities with your physician.

Key Developments

New data presented by UCB at the European Hidradenitis Suppurativa Foundation (EHSF) conference reveal that bimekizumab (BIMZELX®), a dual interleukin-17A and 17F inhibitor, demonstrated substantial and sustained improvements in people with moderate to severe HS over three years. The BE HEARD trials showed that 40.1% of participants achieved total resolution of inflammatory HS lesions, including draining tunnels, at three years (IHS4-100). Additionally, 59.1% and 77.4% reached IHS4-90 and IHS4-75 response levels, respectively. Importantly, the proportion of patients classified with severe HS dropped dramatically from 87.4% at baseline to just 14.7% after three years. Over half (59.4%) of participants improved to mild disease status by IHS4 assessment.

Why This Matters for HS Patients

These findings suggest bimekizumab may offer meaningful, durable reductions in HS disease activity and severity for many patients, including those with longstanding moderate to severe disease. Achieving lesion resolution and milder disease states can improve quality of life and reduce HS complications. However, as with all treatments, individual responses vary and long-term safety monitoring remains essential.

These results are from clinical trial data presented by the manufacturer and should be interpreted with caution until peer-reviewed publications and independent regulatory reviews are available.

References

  1. [1]UCB showcases three-year HS data at EHSF: BIMZELX® achieved inflammatory lesion resolution - PharmiWeb
  2. [2]Bimekizumab demonstrated a favorable safety profile and high levels of efficacy - JAAD
  3. [3]Bimekizumab safety and efficacy data - PubMed
  4. [4]FDA Review Package for Bimekizumab - FDA.gov
  5. [5]New HS Treatments: Latest FDA-Approved Options - myHSteam